|
PL2992098T3
(pl)
|
2013-05-01 |
2019-09-30 |
Ionis Pharmaceuticals, Inc. |
Kompozycje i sposoby modulowania ekspresji hbv i ttr
|
|
CR20160554A
(es)
*
|
2014-05-01 |
2017-03-07 |
Ionis Pharmaceuticals Inc |
Composiciones y métodos para modular la expresión del factor b del complemento
|
|
US10570169B2
(en)
|
2014-05-22 |
2020-02-25 |
Ionis Pharmaceuticals, Inc. |
Conjugated antisense compounds and their use
|
|
EP3151839A4
(en)
*
|
2014-06-06 |
2018-02-28 |
Ionis Pharmaceuticals, Inc. |
Compositions and methods for enhanced intestinal absorption of conjugated oligomeric compounds
|
|
EP3865576A1
(en)
|
2014-12-15 |
2021-08-18 |
Dicerna Pharmaceuticals, Inc. |
Ligand-modified double-stranded nucleic acids
|
|
WO2016196124A2
(en)
*
|
2015-05-29 |
2016-12-08 |
Ascendis Pharma Inc. |
Prodrugs comprising a pyroglutamate linker
|
|
JPWO2017010575A1
(ja)
*
|
2015-07-16 |
2018-04-26 |
協和発酵キリン株式会社 |
β２ＧＰＩ遺伝子発現抑制核酸複合体
|
|
CN105524124B
(zh)
*
|
2015-12-31 |
2018-10-30 |
天津英吉诺科技有限公司 |
一种n-乙酰氨基半乳糖的绿色合成方法
|
|
KR20180103166A
(ko)
|
2016-01-29 |
2018-09-18 |
교와 핫꼬 기린 가부시키가이샤 |
핵산 복합체
|
|
JOP20170057B1
(ar)
|
2016-03-07 |
2022-03-14 |
Arrowhead Pharmaceuticals Inc |
مركبات ترابطية مستهدفة كمركبات علاجية
|
|
WO2017178656A1
(en)
|
2016-04-14 |
2017-10-19 |
Roche Innovation Center Copenhagen A/S |
TRITYL-MONO-GalNAc COMPOUNDS AND THEIR USE
|
|
WO2017188898A1
(en)
|
2016-04-29 |
2017-11-02 |
Nanyang Technological University |
G-quadruplex-containing antisense oligonucleotides
|
|
AU2017287536B9
(en)
|
2016-06-30 |
2021-03-25 |
Kyowa Kirin Co., Ltd. |
Nucleic acid complex
|
|
AU2017296195A1
(en)
|
2016-07-11 |
2019-01-24 |
Translate Bio Ma, Inc. |
Nucleic acid conjugates and uses thereof
|
|
WO2018013999A1
(en)
*
|
2016-07-15 |
2018-01-18 |
Am Chemicals Llc |
Non-nucleosidic solid supports and phosphoramidite building blocks for oligonucleotide synthesis
|
|
JOP20170056B1
(ar)
|
2016-09-02 |
2021-08-17 |
Arrowhead Pharmaceuticals Inc |
مركبات ترابطية مستهدفة
|
|
WO2018067900A1
(en)
*
|
2016-10-06 |
2018-04-12 |
Ionis Pharmaceuticals, Inc. |
Method of conjugating oligomeric compounds
|
|
JP7048574B2
(ja)
|
2017-03-10 |
2022-04-05 |
国立研究開発法人国立成育医療研究センター |
アンチセンスオリゴヌクレオチドおよび糖原病Ｉａ型予防または治療用組成物
|
|
CA3057292A1
(en)
*
|
2017-03-22 |
2018-09-27 |
The Regents Of The University Of California |
Modified oligonucleotides and therapeutic uses thereof
|
|
US11015198B2
(en)
|
2017-04-05 |
2021-05-25 |
Silence Therapeutics Gmbh |
Products and compositions
|
|
CN110603330B
(zh)
|
2017-04-28 |
2023-09-05 |
协和麒麟株式会社 |
寡核苷酸衍生物或其盐
|
|
WO2019027015A1
(ja)
*
|
2017-08-02 |
2019-02-07 |
協和発酵キリン株式会社 |
核酸複合体
|
|
TW201920668A
(zh)
*
|
2017-08-02 |
2019-06-01 |
日商協和醱酵麒麟有限公司 |
核酸複合體
|
|
SG11202002149XA
(en)
*
|
2017-09-14 |
2020-04-29 |
Janssen Biopharma Inc |
Galnac derivatives
|
|
CN111050807B
(zh)
*
|
2017-12-01 |
2024-05-28 |
苏州瑞博生物技术股份有限公司 |
一种核酸、含有该核酸的组合物与缀合物及制备方法和用途
|
|
HRP20250277T1
(hr)
|
2017-12-01 |
2025-05-09 |
Suzhou Ribo Life Science Co., Ltd. |
Dvolančani oligonukleotid, sastav i konjugat koji sadrži dvolančani oligonukleotid, postupak njihove pripreme i upotreba
|
|
CN118291456A
(zh)
|
2017-12-01 |
2024-07-05 |
苏州瑞博生物技术股份有限公司 |
一种核酸、含有该核酸的组合物与缀合物及制备方法和用途
|
|
WO2019105403A1
(zh)
*
|
2017-12-01 |
2019-06-06 |
苏州瑞博生物技术有限公司 |
一种核酸、含有该核酸的组合物与缀合物及制备方法和用途
|
|
CN110944675B9
(zh)
*
|
2017-12-01 |
2024-08-09 |
苏州瑞博生物技术股份有限公司 |
一种核酸、含有该核酸的组合物与缀合物及制备方法和用途
|
|
WO2019105414A1
(zh)
|
2017-12-01 |
2019-06-06 |
苏州瑞博生物技术有限公司 |
一种核酸、含有该核酸的组合物与缀合物及制备方法和用途
|
|
JP7360716B2
(ja)
|
2017-12-01 |
2023-10-13 |
スーチョウ リボ ライフ サイエンス カンパニー、リミテッド |
核酸、当該核酸を含む組成物および複合体ならびに調製方法と使用
|
|
CN110959011B
(zh)
|
2017-12-29 |
2023-03-28 |
苏州瑞博生物技术股份有限公司 |
缀合物及其制备方法和用途
|
|
WO2019140102A1
(en)
|
2018-01-10 |
2019-07-18 |
Translate Bio Ma, Inc. |
Compositions and methods for facilitating delivery of synthetic nucleic acids to cells
|
|
WO2019172286A1
(ja)
|
2018-03-09 |
2019-09-12 |
第一三共株式会社 |
糖原病Ｉａ型治療薬
|
|
US20210155926A1
(en)
*
|
2018-04-05 |
2021-05-27 |
Silence Therapeutics Gmbh |
siRNAs WITH AT LEAST TWO LIGANDS AT DIFFERENT ENDS
|
|
CA3098623A1
(en)
|
2018-05-07 |
2019-11-14 |
Alnylam Pharmaceuticals, Inc. |
Extrahepatic delivery
|
|
WO2020038377A1
(zh)
|
2018-08-21 |
2020-02-27 |
苏州瑞博生物技术有限公司 |
一种核酸、含有该核酸的药物组合物和缀合物及其用途
|
|
JP7376952B2
(ja)
*
|
2018-09-30 |
2023-11-09 |
スーチョウ リボ ライフ サイエンス カンパニー、リミテッド |
ｓｉＲＮＡ複合体及びその調製方法と使用
|
|
GB2579253A
(en)
*
|
2018-11-28 |
2020-06-17 |
Pedanius Therapeutics Ltd |
Antibacterial antisense agents
|
|
US20220127605A1
(en)
|
2018-11-30 |
2022-04-28 |
Kyowa Kirin Co., Ltd. |
Nucleic acid conjugate
|
|
GB201821269D0
(en)
|
2018-12-28 |
2019-02-13 |
Nippon Shinyaku Co Ltd |
Myostatin signal inhibitor
|
|
JP7507495B2
(ja)
|
2018-12-28 |
2024-06-28 |
スーチョウ リボ ライフ サイエンス カンパニー、リミテッド |
核酸、当該核酸を含む組成物及び複合体ならびに調製方法と使用
|
|
CN111377985B
(zh)
*
|
2018-12-29 |
2023-11-10 |
苏州瑞博生物技术股份有限公司 |
化合物和缀合物及其制备方法和用途
|
|
CN111377984B
(zh)
*
|
2018-12-29 |
2024-03-05 |
苏州瑞博生物技术股份有限公司 |
化合物和缀合物及其制备方法和用途
|
|
CN113330117B
(zh)
*
|
2019-01-18 |
2024-05-28 |
苏州瑞博生物技术股份有限公司 |
一种核酸、含有该核酸的组合物与缀合物及制备方法和用途
|
|
CN113227376B
(zh)
|
2019-05-22 |
2024-04-09 |
苏州瑞博生物技术股份有限公司 |
核酸、药物组合物与缀合物及制备方法和用途
|
|
CN113614230B
(zh)
*
|
2019-05-22 |
2024-04-09 |
苏州瑞博生物技术股份有限公司 |
核酸、药物组合物与缀合物及制备方法和用途
|
|
CN113286888B
(zh)
|
2019-05-22 |
2023-12-22 |
苏州瑞博生物技术股份有限公司 |
核酸、药物组合物与缀合物及制备方法和用途
|
|
JP7610848B2
(ja)
|
2019-05-22 |
2025-01-09 |
スーチョウ リボ ライフ サイエンス カンパニー、リミテッド |
核酸、薬物組成物及び複合体ならびに調製方法と使用
|
|
CN111973618B
(zh)
*
|
2019-05-23 |
2024-02-02 |
苏州瑞博生物技术股份有限公司 |
核酸、药物组合物与siRNA缀合物及制备方法和用途
|
|
CN111973619B
(zh)
*
|
2019-05-23 |
2024-01-30 |
苏州瑞博生物技术股份有限公司 |
核酸、含有该核酸的药物组合物与siRNA缀合物及制备方法和用途
|
|
CN113891939B
(zh)
|
2019-05-24 |
2024-04-02 |
苏州瑞博生物技术股份有限公司 |
核酸、药物组合物与缀合物及制备方法和用途
|
|
CN113795582B
(zh)
|
2019-05-24 |
2024-05-24 |
苏州瑞博生物技术股份有限公司 |
核酸、药物组合物与缀合物及制备方法和用途
|
|
CN113795280B
(zh)
*
|
2019-05-24 |
2024-04-05 |
苏州瑞博生物技术股份有限公司 |
核酸、药物组合物与缀合物及制备方法和用途
|
|
CN112007040B
(zh)
*
|
2019-05-31 |
2024-01-30 |
苏州瑞博生物技术股份有限公司 |
用于治疗乙型病毒性肝炎的联合用药物
|
|
JP2022546055A
(ja)
|
2019-08-29 |
2022-11-02 |
スーチョウ リボ ライフ サイエンス カンパニー、リミテッド |
化合物、薬物複合体及びその調製方法と使用
|
|
IL291251B2
(en)
|
2019-09-10 |
2026-06-01 |
Daiichi Sankyo Co Limited |
CONJUGATE OF GalNAC-OLIGONUCLEOTIDE FOR DELIVERY TO LIVER AND MANUFACTURING METHOD THEREOF
|
|
US10973910B1
(en)
|
2019-09-23 |
2021-04-13 |
Koranex Capital |
Neoglycoconjugates as vaccines and therapeutic tools
|
|
WO2021092371A2
(en)
*
|
2019-11-06 |
2021-05-14 |
Alnylam Pharmaceuticals, Inc. |
Extrahepatic delivery
|
|
CN115397471B
(zh)
*
|
2019-11-26 |
2026-01-23 |
诺华股份有限公司 |
包括核酸和半衰期延长基序的化合物
|
|
CN112876534B
(zh)
*
|
2019-11-29 |
2024-02-09 |
苏州瑞博生物技术股份有限公司 |
肝靶向化合物及缀合物
|
|
KR20220133878A
(ko)
*
|
2020-01-29 |
2022-10-05 |
스미또모 가가꾸 가부시끼가이샤 |
핵산 올리고머의 제조 방법
|
|
CN111269279B
(zh)
*
|
2020-02-24 |
2022-08-05 |
陕西师范大学 |
一种在温和条件下制备卤代糖的方法
|
|
IL296660A
(en)
|
2020-03-24 |
2022-11-01 |
Generation Bio Co |
Non-viral DNA vectors and their use for therapeutic expression of factor ix
|
|
IL296662A
(en)
|
2020-03-24 |
2022-11-01 |
Generation Bio Co |
Non-viral dna vectors and uses thereof for expressing gaucher therapeutics
|
|
AU2021244786A1
(en)
|
2020-03-25 |
2022-11-03 |
Risen (Suzhou) Pharma Tech Co., Ltd. |
Stable heavy isotopes in amide functional groups and uses thereof
|
|
CN113683651A
(zh)
*
|
2020-05-19 |
2021-11-23 |
上海京新生物医药有限公司 |
一种GalNAc中间体的制备方法
|
|
MX2022014606A
(es)
|
2020-05-22 |
2023-03-08 |
Wave Life Sciences Ltd |
Composiciones de oligonucleótidos bicatenarios y métodos relacionados con las mismas.
|
|
AU2021288648A1
(en)
|
2020-06-10 |
2023-02-09 |
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. |
Conjugate of double-stranded siRNA analogue
|
|
KR20230135585A
(ko)
|
2020-12-23 |
2023-09-25 |
플래그쉽 파이어니어링 이노베이션스 브이아이, 엘엘씨 |
변형된 trem의 조성물 및 이의 용도
|
|
EP4273245A4
(en)
|
2020-12-29 |
2024-12-11 |
Suzhou Ribo Life Science Co., Ltd. |
NUCLEIC ACID, PHARMACEUTICAL COMPOSITION AND SIRNA CONJUGATE WITH THE NUCLEIC ACID, MANUFACTURING PROCESS THEREOF AND USE THEREOF
|
|
WO2022189861A1
(en)
|
2021-03-08 |
2022-09-15 |
Tollys |
Carbohydrate conjugates of tlr3 ligands and uses thereof
|
|
JP2024515788A
(ja)
|
2021-04-27 |
2024-04-10 |
ジェネレーション バイオ カンパニー |
治療抗体を発現する非ウイルスｄｎａベクター及びその使用
|
|
US20240216535A1
(en)
|
2021-04-27 |
2024-07-04 |
Generation Bio Co. |
Non-viral dna vectors expressing anti-coronavirus antibodies and uses thereof
|
|
WO2022246195A1
(en)
*
|
2021-05-20 |
2022-11-24 |
Olix Us, Inc. |
Functional moieties and their uses and synthetic preparation
|
|
CN115572241B
(zh)
*
|
2021-06-21 |
2024-08-30 |
润佳（苏州）医药科技有限公司 |
双价化合物、偶联物及其用途
|
|
TW202317147A
(zh)
|
2021-07-08 |
2023-05-01 |
日商日本新藥股份有限公司 |
析出抑制劑
|
|
TW202308664A
(zh)
|
2021-07-08 |
2023-03-01 |
日商日本新藥股份有限公司 |
腎毒性減輕劑
|
|
US20240316093A1
(en)
|
2021-07-08 |
2024-09-26 |
Nippon Shinyaku Co., Ltd. |
Nephrotoxicity reducing agent
|
|
EP4372086A4
(en)
|
2021-07-16 |
2026-06-17 |
Suzhou Ribo Life Science Co Ltd |
DOUBLE-STRANDED OLIGONUCLEOTIDE, COMPOSITION AND CONJUGATE CONTAINING A DOUBLE-STRANDED OLIGONUCLEOTIDE, PREPARATION PROCESSES AND USES
|
|
CN117580953B
(zh)
|
2021-07-16 |
2025-07-18 |
苏州瑞博生物技术股份有限公司 |
一种核酸、含有该核酸的组合物与缀合物及制备方法和用途
|
|
EP4380576A4
(en)
*
|
2021-08-03 |
2026-04-29 |
Verve Therapeutics Inc |
RNA TARGETED COMPOSITIONS AND ADMINISTRATION METHODS
|
|
CA3227661A1
(en)
|
2021-08-05 |
2023-02-09 |
Weimin Wang |
1'-alkyl modified ribose derivatives and methods of use
|
|
CA3233113A1
(en)
*
|
2021-09-22 |
2023-03-30 |
Sanegene Bio Usa Inc. |
2'-alkyl or 3'-alkyl modified ribose derivatives for use in the in-vivo delivery of oligonucleotides
|
|
US20230227480A1
(en)
|
2021-10-05 |
2023-07-20 |
Sanegene Bio Usa Inc. |
Polyhydroxylated cyclopentane derivatives and methods of use
|
|
WO2023097251A1
(en)
*
|
2021-11-23 |
2023-06-01 |
Yale University |
Oligonucleotide-containing transcription factor targeting chimeras
|
|
IL314850A
(en)
|
2022-02-22 |
2024-10-01 |
Sanegene Bio Usa Inc |
Ribonucleotide derivatives substituted at the 5' position in the carboxyl group and methods of use
|
|
JPWO2023171804A1
(enExample)
|
2022-03-10 |
2023-09-14 |
|
|
|
EP4493212A1
(en)
|
2022-03-14 |
2025-01-22 |
Generation Bio Co. |
Heterologous prime boost vaccine compositions and methods of use
|
|
EP4495241A1
(en)
|
2022-03-16 |
2025-01-22 |
Daiichi Sankyo Company, Limited |
Chemically-modified oligonucleotide having rnai activity
|
|
IL315659A
(en)
|
2022-03-16 |
2024-11-01 |
Daiichi Sankyo Co Ltd |
siRNA FOR SUPPRESSING EXPRESSION OF TRANSFERRIN RECEPTOR-2
|
|
WO2023207615A1
(zh)
*
|
2022-04-26 |
2023-11-02 |
南京明德新药研发有限公司 |
一类含由天然核苷酸组成突出端的双链RNAi化合物
|
|
WO2023212134A2
(en)
*
|
2022-04-28 |
2023-11-02 |
Dicerna Pharmaceuticals, Inc. |
Methods for synthesis of peracetylgalactosamine-1-pentanoic acid
|
|
EP4522742A2
(en)
|
2022-05-13 |
2025-03-19 |
Alnylam Pharmaceuticals, Inc. |
Single-stranded loop oligonucleotides
|
|
EP4544043A1
(en)
|
2022-06-22 |
2025-04-30 |
Flagship Pioneering Innovations VI, LLC |
Compositions of modified trems and uses thereof
|
|
CN119654412A
(zh)
*
|
2022-06-27 |
2025-03-18 |
中美瑞康核酸技术(南通)研究院有限公司 |
激活补体因子h表达的寡核苷酸调节剂
|
|
EP4547683A2
(en)
|
2022-06-30 |
2025-05-07 |
Alnylam Pharmaceuticals, Inc. |
Cyclic-disulfide modified phosphate based oligonucleotide prodrugs
|
|
IL317824A
(en)
|
2022-07-11 |
2025-02-01 |
Sanegene Bio Usa Inc |
Ribose derivatives modified at the '2' position and methods of use
|
|
CN117903225A
(zh)
*
|
2022-07-29 |
2024-04-19 |
思合基因(北京)生物科技有限公司 |
肝组织靶向递送化合物及其制备方法和其应用
|
|
WO2024031101A1
(en)
|
2022-08-05 |
2024-02-08 |
Sanegene Bio Usa Inc. |
Double stranded rna targeting angiotensinogen (agt) and methods of use thereof
|
|
WO2024040222A1
(en)
|
2022-08-19 |
2024-02-22 |
Generation Bio Co. |
Cleavable closed-ended dna (cedna) and methods of use thereof
|
|
WO2024081954A2
(en)
|
2022-10-14 |
2024-04-18 |
Sanegene Bio Usa Inc. |
Small interfering rna targeting c3 and uses thereof
|
|
AU2023404700A1
(en)
|
2022-12-02 |
2025-07-10 |
Shanghai Argo Biopharmaceutical Co., Ltd. |
Bicyclic abasic nucleic acid analogs and oligomeric compounds prepared therefrom
|
|
JP2025542234A
(ja)
|
2022-12-19 |
2025-12-25 |
セーンジーン バイオ ユーエスエー インコーポレイティド |
低分子干渉ｒｎａ標的化ｃｆｂ及びその使用
|
|
CN116178458A
(zh)
*
|
2022-12-26 |
2023-05-30 |
成都药明康德新药开发有限公司 |
一种糖苷化合物的合成
|
|
WO2024160204A1
(en)
*
|
2023-01-30 |
2024-08-08 |
Primelink Biotherapeutics (Suzhou) Co., Ltd. |
Polymer-oligonucleotide conjugates
|
|
CN120615096A
(zh)
*
|
2023-02-21 |
2025-09-09 |
成都先导药物开发股份有限公司 |
核苷酸类似物及其制备方法和用途
|
|
US20240309383A1
(en)
|
2023-02-24 |
2024-09-19 |
Suzhou Sanegene Bio Inc. |
Small interfering rna targeting hbv and uses thereof
|
|
WO2024186673A2
(en)
|
2023-03-03 |
2024-09-12 |
Sanegene Bio Usa Inc. |
Small interfering rna targeting apoc3 and uses thereof
|
|
WO2024188174A1
(zh)
|
2023-03-10 |
2024-09-19 |
苏州瑞博生物技术股份有限公司 |
一种药物组合物及其用途
|
|
WO2024238385A2
(en)
|
2023-05-12 |
2024-11-21 |
Alnylam Pharmaceuticals, Inc. |
Single-stranded loop oligonucleotides
|
|
WO2024245381A1
(zh)
|
2023-06-01 |
2024-12-05 |
广东东阳光药业股份有限公司 |
一种新型的双链siRNA、其缀合物及其用途
|
|
CN116854771A
(zh)
*
|
2023-06-14 |
2023-10-10 |
北京炫景瑞医药科技有限公司 |
GalNAc衍生物、缀合物、组合物以及它们的用途
|
|
JP2026522625A
(ja)
|
2023-06-21 |
2026-07-08 |
セーンジーン バイオ ユーエスエー インコーポレイティド |
プロタンパク質転換酵素サブチリシン・ケキシン９型（ｐｃｓｋ９）を標的とする二本鎖ｒｎａ、およびその使用方法
|
|
CN119219716A
(zh)
*
|
2023-06-30 |
2024-12-31 |
上海维申医药有限公司 |
新型GalNAc的靶向递送片段及其制备和应用
|
|
CN122029174A
(zh)
*
|
2023-07-19 |
2026-05-12 |
维申医药(南通)有限公司 |
新型GalNAc的靶向递送片段及其制备和应用
|
|
AU2024301344A1
(en)
|
2023-07-24 |
2026-01-29 |
Sanegene Bio Usa Inc. |
Lipid-based enhancement agent for rna delivery and therapy
|
|
EP4756027A1
(en)
|
2023-08-04 |
2026-06-10 |
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. |
Double-stranded ribonucleic acid targeting pd-l1
|
|
TW202515586A
(zh)
|
2023-08-09 |
2025-04-16 |
大陸商北京福元醫藥股份有限公司 |
抑制DGAT2基因表達的siRNA、siRNA綴合物或其前藥和藥物組合物及用途
|
|
WO2025042786A1
(en)
|
2023-08-18 |
2025-02-27 |
Flagship Pioneering Innovations Vi, Llc |
Compositions comprising circular polyribonucleotides and uses thereof
|
|
CN121729496A
(zh)
|
2023-08-31 |
2026-03-24 |
正大天晴药业集团股份有限公司 |
靶向凝血因子xi的双链核糖核酸
|
|
CN117384226B
(zh)
*
|
2023-09-14 |
2025-12-26 |
苏州盛诺维生物科技有限公司 |
一种GalNAc类化合物的合成工艺
|
|
AU2024368057A1
(en)
|
2023-10-27 |
2026-05-21 |
Suzhou Ribo Life Science Co., Ltd. |
Pharmaceutical composition and use thereof
|
|
WO2025096809A1
(en)
|
2023-10-31 |
2025-05-08 |
Korro Bio, Inc. |
Oligonucleotides comprising phosphoramidate internucleotide linkages
|
|
US20250161347A1
(en)
|
2023-11-22 |
2025-05-22 |
Flagship Pioneering Innovations Vii, Llc |
Methods and compositions for treating non-alcoholic fatty liver disease
|
|
CN120209036A
(zh)
*
|
2023-12-26 |
2025-06-27 |
广东东阳光药业股份有限公司 |
一种新型的化合物及其用途
|
|
WO2025155911A1
(en)
|
2024-01-18 |
2025-07-24 |
Proqr Therapeutics Ii B.V. |
Antisense oligonucleotides for the treatment of hurler syndrome
|
|
TW202602932A
(zh)
|
2024-03-28 |
2026-01-16 |
美商萊西亞醫療公司 |
用於降解甲狀腺刺激荷爾蒙受體自體抗體之胞溶體靶向雙功能分子
|
|
WO2025228441A2
(en)
|
2024-04-30 |
2025-11-06 |
Sanegene Bio Usa Inc. |
Small interfering rna targeting inhbe and uses thereof
|
|
CN118146284B
(zh)
*
|
2024-05-08 |
2024-07-26 |
北京悦康科创医药科技股份有限公司 |
一种GalNAc化合物、其与寡核苷酸缀合物及制备方法
|
|
WO2025245188A2
(en)
|
2024-05-21 |
2025-11-27 |
Flagship Pioneering Innovations Vii, Llc |
Methods of treating liver steatosis and non-alcoholic fatty liver disease
|
|
WO2026017140A2
(en)
|
2024-07-18 |
2026-01-22 |
Sanegene Bio Usa Inc. |
Small interfering rna targeting fxi and uses thereof
|
|
WO2026041067A2
(en)
|
2024-08-20 |
2026-02-26 |
Sanegene Bio Usa Inc. |
Small interfering rna targeting myostatin (mstn) and uses thereof
|
|
WO2026046411A1
(en)
|
2024-09-02 |
2026-03-05 |
Sanegene Bio Usa Inc. |
Small interfering rna targeting plasminogen (plg) and uses thereof
|
|
WO2026085495A1
(en)
|
2024-10-18 |
2026-04-23 |
Generation Bio Co. |
Synthetic partially single-stranded nucleic acid compositions and uses and methods therefor
|
|
WO2026122478A1
(en)
|
2024-12-02 |
2026-06-11 |
Korro Bio, Inc. |
Extrahepatic delivery formulations and methods
|
|
WO2026131490A1
(en)
|
2024-12-20 |
2026-06-25 |
Ribocure Pharmaceuticals Ab |
Oligonucleotide, oligonucleotide conjugate and composition, and use thereof
|
|
US20260226475A1
(en)
|
2025-01-27 |
2026-08-06 |
Sanegene Bio Usa Inc. |
Small interfering rna targeting acvr1c and uses thereof
|